White Matter Hyperintensity

Introduction

White matter hyperintensities (WMH) are common brain changes observed on magnetic resonance imaging (MRI) scans, particularly in the aging population.^[1] These areas appear brighter than normal brain tissue on specific MRI sequences.^{[1], [2], [3]} and represent subtle damage to the brain’s white matter, which consists of nerve fibers that connect different regions of the brain. The volume of white matter hyperintensities (WMHV) is often quantified using automated segmentation methods or visual grading scales to assess their burden.^{[1], [4], [5]} WMH can manifest in different locations, such as periventricular (around the brain’s ventricles) and deep white matter regions.^[6]

Biological Basis

WMH are considered a manifestation of cerebral small vessel disease, reflecting damage to the small blood vessels within the brain.^[7] This damage can lead to impaired integrity of the white matter microstructure, which can be assessed through various neuroimaging metrics like fractional anisotropy (FA), mean diffusivity (MD), radial diffusivity (RD), axial diffusivity (AxD), and peak width of skeletonized mean diffusivity (PSMD).^[8] The presence and extent of WMH are highly heritable, indicating a significant genetic influence on their development.^{[1], [9]} Genome-wide association studies (GWAS) have identified specific genetic variants associated with WMH. For example, genetic variation in the PLEKHG1 gene has been linked to WMH.^[5] and exome chip analysis has identified low-frequency and rare variants in MRPL38.^[3] Research suggests that common genetic variations may indicate distinct underlying causes for periventricular and deep WMH.^[6]Furthermore, the genetic architecture of WMH may vary in individuals with hypertensive versus non-hypertensive ischemic stroke.^[10]

Clinical Relevance

The presence of white matter hyperintensities carries significant clinical relevance, as they are associated with an increased risk of several adverse health outcomes. These include stroke.^{[2], [5], [11]}vascular cognitive impairment, dementia.^[1] and even death.^[1] WMH are correlated with general cognitive disorders.^[4]and their severity (sometimes referred to as leukoaraiosis) can predict clinical outcomes after ischemic stroke.^[12]They are also notably increased in specific subtypes of small vessel stroke.^[13] The progression of white matter lesions is also observed in conditions like cerebral amyloid angiopathy.^[14]

Social Importance

Given their strong association with stroke, dementia, and cognitive decline, white matter hyperintensities represent a substantial public health concern, particularly in an aging global population.^[1]These conditions are major causes of disability, morbidity, and mortality, imposing considerable burdens on individuals, caregivers, and healthcare systems. Understanding the genetic and biological underpinnings of WMH is crucial for developing strategies for early detection, prevention, and treatment, ultimately aiming to mitigate their impact on brain health and overall quality of life.

Methodological and Analytical Constraints

Many investigations into white matter hyperintensities are constrained by their study design and statistical power, particularly when identifying genetic variants with subtle effects. Some analyses operate with relatively small sample sizes, such as cohorts reduced to a few hundred valid participants after stringent quality control, which can limit the statistical power needed to detect novel associations in genome-wide association studies.^[4] This often leads to a reliance on meta-analyses to boost power, yet even then, a lack of independent replication for newly identified findings remains a significant hurdle, necessitating further evidence to confirm their robustness.^[15] Furthermore, the quantification of white matter hyperintensities presents its own set of challenges. Phenotypic variability across studies is common, arising from differences in imaging protocols, lesion segmentation methods, and the use of both automated volumetric tools and visual grading scales.^[5] While efforts are made to harmonize these measures and ensure high inter-rater reliability, subtle biases and differences can persist, potentially influencing the estimated effects of genetic variants.^[16]The inherent skewness of white matter hyperintensity volumes often requires log transformation to achieve a normal distribution for statistical analysis, and the exclusion of extreme outliers, while necessary for robust results, can also subtly impact the representativeness of the remaining sample.^[4]Additionally, combining data from diverse populations, such as community-based and stroke cohorts, while increasing sample size, introduces the potential for subtle influences on effect estimates due to population selection biases.^[16]

Limited Generalizability and Population Specificity

A significant limitation in understanding white matter hyperintensities lies in the restricted demographic diversity of many cohorts, primarily focusing on individuals of European genetic descent. This narrow scope means that findings may not be directly applicable or generalizable to other ethnic or ancestral populations, where genetic architectures and environmental exposures can differ substantially.^[4] Consequently, while some multi-ethnic studies have been conducted, the underrepresentation of non-European ancestries limits the ability to fully elucidate the global genetic landscape of white matter hyperintensities and understand potential population-specific genetic influences.^[15] Further generalizability issues stem from specific cohort selection criteria. Studies often include only non-demented individuals or those within particular age ranges, which, while reducing confounding factors, may not reflect the full spectrum of the trait across the lifespan or in clinically diverse populations.^[4] For age-related traits like white matter hyperintensities, studying older populations introduces a survival bias, as only individuals who have lived to recruitment age are included, potentially influencing the estimated genetic effects.^[16] Such selection biases can restrict the applicability of findings to the broader population, highlighting the need for more diverse and representative cohorts.

Unexplained Variance and Environmental Factors

Despite significant progress in identifying genetic variants, a substantial portion of the heritability of white matter hyperintensities remains unexplained, indicating a complex polygenic architecture that is not yet fully characterized.^[17] While heritability estimates range, they rarely account for the entirety of the observed phenotypic variance, suggesting that many contributing genetic factors, particularly those with smaller effects or rare variants, are still to be discovered.^[8] This “missing heritability” points to the intricate interplay of numerous genetic loci, potentially including gene-gene interactions, that contribute to the development and progression of white matter hyperintensities.

Beyond genetic factors, environmental exposures and lifestyle choices play a critical, yet often unquantified, role in the etiology of white matter hyperintensities. Differences in environmental factors, along with potential epigenetic modifications, can contribute significantly to phenotypic variability observed across individuals and cohorts, potentially altering the manifestation and severity of the trait.^[5]The genetic architecture of white matter hyperintensities may also differ based on co-existing conditions, such as hypertension or stroke subtypes, further complicating the understanding of underlying mechanisms.^[5] These complex gene-environment interactions and remaining knowledge gaps underscore the multifactorial nature of white matter hyperintensities and highlight the need for integrative research approaches.

Variants

Genetic variations play a crucial role in influencing the susceptibility and progression of white matter hyperintensities (WMH), which are visible brain lesions associated with aging, neurological disorders, and vascular risk factors. Several genes and their specific variants have been implicated in the development of WMH by affecting various biological pathways, including inflammation, extracellular matrix integrity, and cellular homeostasis. Studies leveraging large population cohorts have identified numerous genetic loci associated with WMH volume and other markers of cerebral small vessel disease, highlighting the complex genetic architecture underlying this condition.^[8] One significant gene associated with WMH is PLEKHG1, with the intronic variant rs275350 having reached genome-wide significance for its association with WMH volumes.^[16] PLEKHG1encodes a guanine nucleotide exchange factor, a protein critical for activating small GTPases that regulate cell signaling, cytoskeletal organization, and membrane trafficking, suggesting its involvement in maintaining the structural integrity or function of brain cells and vasculature. Another variant,rs6940540 , also contributes to the genetic landscape of PLEKHG1 and its potential impact on brain health. Similarly, SH3PXD2A, located at chromosome 10q24.33, has been identified as a locus associated with WMH.^[8] SH3PXD2A is involved in cell adhesion and extracellular matrix degradation, processes vital for vascular integrity and tissue remodeling, and variants such as rs4630220 , rs3758575 , and rs12357919 may modulate these functions, thereby influencing WMH risk.

The Tripartite Motif (TRIM) family genes, including TRIM47 and TRIM65, are also relevant to WMH, with TRIM47 being situated within the 17q25.1 locus, which is consistently associated with WMH.^[8] TRIM proteins often function as E3 ubiquitin ligases, regulating protein stability and degradation pathways involved in immune responses, inflammation, and cellular stress. Variants like rs3744020 in TRIM47, and rs34974290 , rs7214628 , rs55823223 in TRIM65, could alter these regulatory processes, impacting the brain’s resilience to injury or disease. Furthermore,EFEMP1, located at 2p16.1, is associated with WMH and encodes an extracellular matrix protein crucial for tissue organization and vascular wall integrity.^[8] Variants like rs7596872 , rs78857879 , and rs3762515 could lead to subtle alterations in the extracellular environment, affecting the structural support and function of white matter.

Other genes, such as KLHL24, NMT1, and DCAKD, have been identified as eGenes (expression quantitative trait loci genes) for WMH, meaning their gene expression levels are associated with WMH risk variants.^[8] KLHL24 is a BTB-Kelch protein involved in ubiquitination and proteasomal degradation, processes vital for maintaining protein homeostasis, and changes in its expression, potentially influenced by rs830179 or rs6797002 , could affect cellular health. NMT1 (N-Myristoyltransferase 1) performs protein myristoylation, a lipid modification essential for protein targeting and function in various signaling pathways. DCAKD(Deoxycytidine Kinase Associated Kinase Domain) is involved in nucleotide metabolism, impacting cellular energy and DNA repair mechanisms. Variants such asrs8071429 in NMT1 and rs55897749 in DCAKD might modulate the expression or function of these proteins, contributing to WMH pathology.^[18] Finally, NBEAL1 is a gene near rs72934505 , a top association SNP identified in WMH meta-analyses.^[18] NBEAL1 (Neurobeachin-like 1) plays a role in membrane trafficking and protein sorting, particularly important in neuronal function and maintenance, suggesting that variants like rs72934505 and rs2351524 could affect neuronal integrity. The VCAN gene encodes Versican, a major component of the extracellular matrix crucial for brain tissue structure and inflammation regulation. Its antisense RNA, VCAN-AS1, may regulate VCAN expression, and the variant rs7733216 could impact extracellular matrix stability or inflammatory responses. While less characterized, C16orf95 and its variants, including rs12928520 , rs12921170 , and rs4843553 , are also associated with WMH, implying a role in fundamental cellular processes that, when disrupted, contribute to the development of these brain lesions.^[8]

Key Variants

RS ID	Gene	Related Traits
rs34974290 rs7214628 rs55823223	TRIM65	white matter hyperintensity white matter microstructure
rs3744020	TRIM47	neuroimaging white matter hyperintensity glomerular filtration rate
rs7596872 rs78857879 rs3762515	EFEMP1	Inguinal hernia white matter hyperintensity brain attribute perivascular space
rs830179 rs6797002	KLHL24	white matter hyperintensity
rs7733216	VCAN, VCAN-AS1	heel bone mineral density white matter integrity mean fractional anisotropy white matter hyperintensity white matter microstructure
rs275350 rs6940540	PLEKHG1	brain connectivity attribute brain volume neuroimaging white matter hyperintensity cortical thickness
rs8071429 rs55897749	NMT1, DCAKD	heel bone mineral density white matter hyperintensity heel bone mineral density, sex hormone-binding globulin
rs4630220 rs3758575 rs12357919	SH3PXD2A	white matter hyperintensity
rs12928520 rs12921170 rs4843553	C16orf95	neuroimaging white matter hyperintensity brain volume white matter microstructure
rs72934505 rs2351524	NBEAL1	white matter hyperintensity white matter integrity

Defining White Matter Hyperintensities and Related Terminology

White matter hyperintensities (WMH) are precisely defined as areas of increased signal intensity observed on T2-weighted fluid-attenuated inversion recovery (FLAIR) magnetic resonance imaging (MRI) sequences of the brain.^[16]These lesions reflect underlying changes in brain white matter, often indicative of small vessel disease, and are commonly observed in the aging population.^{[1], [7]}The quantitative aspect of this trait is frequently referred to as white matter hyperintensity volume (WMHV), which serves as a key phenotype in genetic and clinical research.^{[4], [5]}Other terms used synonymously or to describe related concepts include “leukoaraiosis,” particularly in older literature or when referring to diffuse white matter changes, and “cerebral white matter lesions” or “age-related white matter changes,” highlighting their progressive nature and association with aging.^{[14], [19], [20]}

Classification and Clinical Significance

While WMH can be broadly classified as a manifestation of cerebral small vessel disease, specific standardized disease classifications often focus on the underlying etiology rather than WMH alone.^[7] However, WMH itself is frequently categorized by severity, which is treated as a continuous quantitative outcome phenotype for research.^{[4], [21]}The clinical significance of WMH is substantial, as they are correlated with cognitive disorders, an increased risk of stroke, vascular cognitive impairment, and dementia.^{[1], [2], [4]}Furthermore, WMHV has been observed to be increased in specific small vessel stroke subtypes, underscoring its role as a biomarker for cerebrovascular health.^[13] The recognition of heterogeneity in age-related white matter changes also suggests the potential for future classifications based on distinct pathological mechanisms.^[20]

Approaches and Criteria

The primary diagnostic and criteria for WMH rely on advanced neuroimaging techniques, specifically MRI with FLAIR sequences.^[16] approaches range from semi-automated to fully automated segmentation methods. Semi-automated techniques, such as DISPunc or Jim image analysis software, involve initial manual marking of a lesion border (seed) followed by automated outlining based on signal intensity gradients, with subsequent visual inspection and manual correction.^[16] Fully automated methods, like the Brain Intensity Abnormality Classification Algorithm (BIANCA), utilize supervised learning approaches (e.g., k-nearest neighbor algorithm) to assign a probability per voxel of being WMH, with total WMHV calculated from voxels exceeding a defined probability threshold, often 0.9, within a white matter mask.^{[15], [16], [22]} Another automated method defines WMHs as points greater than 3.5 standard deviations from the mean signal in white matter, with final segmentation based on a Bayesian approach combining spatial priors and tissue class constraints.^[4]For robust analysis, WMHV values are typically adjusted for total intracranial volume (TICV or ICV) to account for natural head size differences and are often log-transformed to achieve a normal distribution due to their skewed nature.^{[4], [5], [15], [16]} Quality control measures, such as the exclusion of extreme outliers (e.g., values greater or smaller than 5.5-fold standard deviation from the mean), are also applied to ensure data integrity.^[4]

Causes of White Matter Hyperintensity

White matter hyperintensities (WMH) are common findings on brain magnetic resonance imaging (MRI) and represent areas of altered white matter integrity. Their presence is associated with an increased risk of stroke, dementia, and death, highlighting their clinical importance.^[2] The development of WMH is multifactorial, stemming from a complex interplay of genetic predispositions, environmental exposures, age-related changes, and various comorbidities.

Genetic Influences and Heritability

Genetic factors play a substantial role in the susceptibility to white matter hyperintensities, which are highly heritable.^[1] Studies have consistently demonstrated genetic variance in WMH volume, with heritability observed in various populations, including hypertensive sibships and individuals from large cohorts like the Framingham Study.^[9] Genome-wide association studies (GWAS) have identified numerous common genetic variants and independent risk loci associated with WMH burden across diverse ethnic groups, including European, African, Hispanic, and Asian ancestries.^[23] For instance, a locus in an intron of PLEKHG1 (rs275350 ) has been identified at genome-wide significance, suggesting its involvement in WMH pathogenesis.^[16] Furthermore, rare and low-frequency variants, such as those in MRPL38, have also been implicated through exome chip analyses.^[3] Distinct genetic influences may contribute to different types of WMH, as common genetic variations indicate separate causes for periventricular and deep white matter hyperintensities.^[24]Mendelian forms of cerebral small vessel disease, such as CADASIL (Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy), also demonstrate a significant genetic component, with heritability of lesion volume and evidence for genetic modifiers influencing disease expression.^[25] These genetic underpinnings highlight the complex polygenic nature of WMH, where the cumulative effect of multiple inherited variants contributes to an individual’s overall risk.^[26]

Environmental and Lifestyle Factors

Beyond genetics, a range of environmental and lifestyle factors significantly contribute to the development and progression of white matter hyperintensities. Hypertension is a well-established risk factor, with WMH often related to elevated blood pressure.^[27]Other cardiovascular risk factors, such as diabetes, hyperlipidemia, and smoking, are also recognized contributors, promoting microvascular damage and impaired cerebral blood flow that can lead to white matter changes. These treatable conditions represent modifiable risk factors, and their management can influence the trajectory of WMH.^[21]Socioeconomic factors and geographic influences may also play a role, indirectly impacting WMH through disparities in healthcare access, diet, and exposure to environmental stressors. While specific details on direct environmental exposures like diet or pollutants are not extensively detailed in all contexts, the broader concept of population structure and relatedness in multi-ethnic genetic studies suggests that environmental heterogeneity across different populations could modulate WMH burden.^[8]Lifestyle choices throughout mid-life, particularly those affecting cardiovascular health, are critical in determining an individual’s risk for WMH later in life.^[21]

Gene-Environment Interactions

The development of white matter hyperintensities is often a result of intricate gene-environment interactions, where genetic predispositions can modify an individual’s susceptibility to environmental triggers. For example, the genetic architecture of WMH has been shown to differ between hypertensive and non-hypertensive ischemic stroke patients, indicating that genetic risk factors may exert varying effects depending on an individual’s blood pressure status.^[10]This highlights that certain genetic profiles might confer greater vulnerability to the pathological effects of environmental stressors like hypertension.

Understanding these gene-environment interactions is crucial for developing precision interventions, as they can inform whether modifying dementia risk factors in mid-life will be effective, especially in individuals with a high genetic risk for WMH.^[21] The interplay suggests that while some individuals may have a genetic resilience to adverse environmental conditions, others with specific genetic variants may experience a more pronounced pathological response, leading to more severe WMH. Therefore, personalized approaches considering both genetic and environmental factors are essential for preventing and managing WMH.

Age and Comorbidity-Related Pathways

Aging is a primary and inescapable risk factor for white matter hyperintensities, which become increasingly common in the elderly population.^[1] As individuals age, a variety of physiological changes occur, including endothelial dysfunction, arterial stiffening, and impaired cerebral autoregulation, all of which contribute to the vulnerability of the cerebral white matter. These age-related changes can lead to chronic hypoperfusion and ischemia, ultimately resulting in the demyelination, axonal loss, and gliosis characteristic of WMH.

Furthermore, WMH are intimately linked with several comorbidities, serving as a critical marker of cerebral small vessel disease.^[21]They are associated with an increased risk of stroke, particularly small vessel stroke subtypes, and contribute significantly to cognitive impairment, dementia, and overall disability.^[13] Conditions like cerebral amyloid angiopathy, characterized by amyloid-beta deposition in cerebral blood vessels, are also associated with WMH progression.^[14] The presence and severity of WMH are correlated with cognitive disorders, underscoring their role as a shared pathological pathway in various neurological and cerebrovascular diseases.^[4]

Defining White Matter Hyperintensities and Their Impact

White matter hyperintensities (WMH) are distinct lesions observed as bright areas on T2-weighted fluid-attenuated inversion recovery (FLAIR) magnetic resonance imaging (MRI) scans of the brain.^[7]These lesions are a common finding in the aging population and are widely recognized as a key indicator of cerebral small vessel disease.^[1] Automated algorithms are frequently employed to segment WMH by identifying regions with signal intensity significantly higher than the average signal in surrounding white matter, enabling quantitative analysis.^[22]From a clinical perspective, WMH are profoundly significant, serving as strong predictors for adverse neurological outcomes, including an elevated risk of stroke, vascular cognitive impairment, and various forms of dementia.^[2] The volume and progression of these hyperintensities correlate with the severity of neurological conditions and are indicative of ongoing brain damage.^[14] Pathological studies suggest that WMH represent areas of demyelination, axonal loss, glial scarring (gliosis), and sometimes microinfarcts within the brain’s delicate white matter tracts.^[28]

Genetic Architecture and Heritability

White matter hyperintensities exhibit a substantial genetic component, with numerous studies confirming their significant heritability across diverse populations.^[9] Genome-wide association studies (GWAS) have been pivotal in uncovering multiple genetic loci associated with WMH burden.^[23] These investigations reveal that WMH are a complex trait influenced by both common genetic variants and, as shown by exome chip analysis and whole-exome sequencing, low-frequency and rare variants.^[3] Further research indicates that different topographical distributions of WMH, specifically periventricular and deep white matter hyperintensities, may be influenced by distinct genetic factors.^[24]This suggests that the underlying biological mechanisms contributing to their formation might vary based on brain region. Moreover, the genetic architecture of WMH can differ between individuals with and without hypertension, particularly in the context of ischemic stroke.^[10] underscoring a complex interplay between genetic predispositions and clinical risk factors.

Key Genes and Molecular Pathways

The identification of specific genes involved in white matter hyperintensities provides crucial insights into the molecular and cellular pathways that contribute to their development. Genetic variations in PLEKHG1, for example, have been consistently associated with WMH.^[16] PLEKHG1encodes a protein that functions as a Rho guanine nucleotide exchange factor, indicating its role in fundamental cellular processes such as cell signaling, organization of the cytoskeleton, and cell migration, all of which are vital in the brain and vascular tissues where this gene is expressed.^[16] Alterations in these pathways could compromise the integrity of blood vessels or the function of glial cells, thereby promoting WMH formation.

Advanced genomic techniques like whole-exome sequencing have additionally highlighted the involvement of genes such as HTRA1 and EGFL8 in WMH.^[29] HTRA1(High-Temperature Requirement A Serine Peptidase 1) is a serine protease critical for extracellular matrix remodeling and growth factor signaling, and its dysfunction is known to contribute to small vessel disease.EGFL8(Epidermal Growth Factor-Like Domain Multiple 8) plays a role in vascular development and angiogenesis, processes essential for maintaining healthy brain microvasculature. Furthermore, variants inMRPL38 (Mitochondrial Ribosomal Protein L38) have been linked to WMH.^[3] implicating mitochondrial function and cellular metabolism as potential contributors to white matter vulnerability. Collectively, these genes emphasize the interconnectedness of vascular health, extracellular matrix integrity, and cellular metabolic pathways in preserving the structural integrity of white matter.

Pathophysiological Basis and Systemic Associations

The primary pathophysiological process underlying white matter hyperintensities is frequently cerebral small vessel disease, a condition characterized by damage to the brain’s small arteries, arterioles, capillaries, and venules.^[7] This microvascular damage can lead to compromised blood flow, chronic hypoperfusion, and disruption of the blood-brain barrier, which in turn results in tissue injury, demyelination, and ultimately the visible hyperintensities on MRI.^[28] Evidence suggests that microstructural damage in normal-appearing white matter, detectable through advanced imaging modalities such as diffusion tensor imaging, often precedes the appearance of overt WMH, indicating a continuum of white matter pathology.^[30]Systemic factors, most notably chronic hypertension, are strongly associated with both the presence and severity of WMH.^[1] Persistent high blood pressure can induce structural changes in cerebral small vessels, such as arteriosclerosis, which impairs their function and directly contributes to WMH development.^[10]Other cardiovascular risk factors also play a significant role, suggesting that WMH are not isolated cerebral phenomena but rather intricate manifestations of broader systemic vascular health issues and homeostatic disruptions that impact the delicate environment of the brain’s white matter.^[15]

Vascular and Endothelial Dysfunction Pathways

White matter hyperintensities (WMH) are strongly associated with cerebral small vessel disease (CSVD) and hypertension, indicating a central role for vascular health in their pathogenesis.^[1] Chronic hypoperfusion injury, often stemming from compromised small vessel function, is a molecular pathology implicated in the origin of these lesions.^[31]This involves dysregulation of endothelial cells and vascular smooth muscle, leading to impaired blood-brain barrier integrity and reduced cerebral blood flow, which are critical for maintaining the metabolic demands and structural integrity of white matter. Interventions targeting blood pressure, such as intensive versus standard control, have been shown to influence the progression of cerebral white matter lesions.^[32]

Genetic and Epigenetic Regulatory Mechanisms

Genetic variation significantly influences white matter hyperintensity volume, with studies identifying numerous loci associated with this trait.^[4] For instance, genetic variation in PLEKHG1 is robustly associated with WMH.^[16] PLEKHG1encodes a pleckstrin homology and Rho guanine nucleotide exchange factor, suggesting its involvement in intracellular signaling cascades that regulate cytoskeletal dynamics and cell adhesion, potentially impacting vascular integrity or glial cell function within the white matter. Additionally, whole-exome sequencing has revealed roles forHTRA1 and EGFL8 in WMH.^[29]

Cellular Stress and Inflammatory Responses

White matter hyperintensities often arise from chronic hypoperfusion, which induces cellular stress within the brain parenchyma.^[31] This stress triggers various signaling pathways, including those that regulate HIF-1alpha levels, apoptosis, and inflammation, as observed in studies on ischemic preconditioning.^[33] Receptor activation on glial cells and endothelial cells initiates intracellular signaling cascades in response to hypoxia or inflammatory stimuli, leading to glial activation, demyelination, and axonal damage. The dysregulation of these pathways, coupled with aberrant feedback loops, can perpetuate the cycle of injury, contributing to the progressive nature of WMH.

Metabolic Homeostasis and Bioenergetic Pathways

The genetic locus containing PLEKHG1 also includes MTHFD1L, methylenetetrahydrofolate dehydrogenase (NADP+ dependent)1 likegene.^[16] hinting at the involvement of metabolic pathways in WMH. MTHFD1Lplays a crucial role in folate-dependent one-carbon metabolism, a pathway essential for nucleotide biosynthesis, amino acid metabolism, and various methylation reactions vital for cellular function and repair. Disruptions in energy metabolism, biosynthesis, or catabolism can compromise the high metabolic demands of oligodendrocytes and axons, making white matter particularly vulnerable to damage. Maintaining metabolic regulation and flux control is therefore critical for preserving myelin integrity and axonal function, and their impairment likely contributes to WMH pathogenesis.

Systems-Level Integration and Disease Progression

White matter hyperintensities are not isolated pathologies but are intricately linked to broader neurological conditions, including stroke, vascular cognitive impairment, and dementia.^[1]This indicates extensive pathway crosstalk and network interactions between vascular dysregulation, neuroinflammation, and neurodegeneration. For example, cerebral amyloidosis, a hallmark of Alzheimer’s disease, is associated with WMH, suggesting a shared or interacting pathological mechanism.^[34]The emergent properties of these complex networks, influenced by both genetic predispositions and environmental factors like hypertension, contribute to the multifactorial nature of WMH. Understanding these integrated systems is crucial for identifying therapeutic targets that can address the diverse mechanisms underlying white matter damage and its progression.

Prognostic Value and Risk Stratification in Neurological Disorders

White matter hyperintensities (WMH) serve as critical prognostic indicators across a spectrum of neurological conditions, offering insights into disease progression and long-term outcomes.^[2]The severity and volume of WMH are significantly correlated with clinical outcomes following ischemic stroke, including susceptibility to infarct growth in acute stroke.^[12]Furthermore, WMH are associated with an increased risk of cognitive disorders and can contribute to the development of dementia in individuals with mild cognitive impairment.^[4]Identifying individuals with a higher burden of WMH allows for improved risk stratification, facilitating personalized medicine approaches and the implementation of targeted prevention strategies for conditions like lacunar stroke, where genetic associations with WMH confer risk.^[5]The presence and evolution of WMH also have implications for age-related cognitive decline, with studies showing a relation between WMH and a decline in intelligence among healthy octogenarians.^[35]Polygenic risk scores for WMH volume have been significantly associated with Alzheimer’s disease, highlighting their utility in identifying high-risk individuals for neurodegenerative conditions.^[15]Longitudinal monitoring of WMH progression can therefore inform clinicians about a patient’s trajectory, potentially guiding early interventions to mitigate adverse neurological events and cognitive decline.^[14]

Guiding Clinical Management and Monitoring Disease Progression

The quantification of WMH is a valuable tool in clinical practice for diagnostic utility, guiding treatment selection, and establishing monitoring strategies. Automated segmentation algorithms, such as BIANCA, enable robust and reproducible of WMH, which is crucial for both clinical assessment and research into small vessel disease.^[22]This precise helps in identifying specific stroke subtypes, as WMH volume is notably increased in small vessel stroke.^[13]For conditions like multiple sclerosis, the quantification of MRI lesion load, including WMH, is essential for monitoring disease activity and assessing treatment response.^[36]Beyond diagnosis, WMH measurements aid in risk assessment for various cerebrovascular pathologies. For instance, the progression of white matter lesions in cerebral amyloid angiopathy can be monitored, providing insights into disease activity and potential complications like hemorrhages.^[14]The ability to accurately track changes in WMH volume over time supports informed clinical decisions regarding therapeutic adjustments and patient management, underscoring their role as a biomarker for cerebral small vessel disease and its contribution to aging and neurodegeneration.^[7]

Genetic and Comorbid Associations of White Matter Hyperintensities

WMH are intricately linked with a range of neurological and systemic comorbidities, representing a common manifestation of vascular brain injury and neurodegeneration.^[2] There is strong evidence for a significant genetic component influencing WMH volume, with numerous genome-wide association studies identifying specific genetic variations, such as in PLEKHG1, HTRA1 and EGFL8, associated with WMH.^[5]This genetic architecture can differ in patient populations, such as between hypertensive and non-hypertensive ischemic stroke patients, suggesting diverse underlying pathological mechanisms.^[10]WMH are frequently observed alongside conditions such as stroke, major depressive disorder, and Alzheimer’s disease, reflecting overlapping pathophysiological pathways, particularly those related to microvascular dysfunction.^[15]Polygenic risk scores for WMH volume and other white matter integrity measures, like mean diffusivity, show significant genetic correlation with MRI-confirmed lacunar stroke and major depressive disorder.^[15] Understanding these multifaceted associations is crucial for a holistic approach to patient care, enabling clinicians to consider the broader implications of WMH for a patient’s overall health and to address related complications or syndromic presentations proactively.^[37]

Frequently Asked Questions About White Matter Hyperintensity

These questions address the most important and specific aspects of white matter hyperintensity based on current genetic research.

---

1. My parents have memory issues. Will I get these brain changes too?

Yes, there’s a strong genetic influence on these brain changes, so they can run in families. If your parents have them, you might have a higher genetic predisposition. However, while genetics play a significant role, they don’t tell the whole story, and other factors also contribute to their development.

2. Can my daily habits affect these brain spots?

While genetics are a major factor, these brain changes are linked to damage in your brain’s small blood vessels. Managing your overall health, especially factors like blood pressure (hypertension), is important. Good daily habits that support cardiovascular health can indirectly help maintain the integrity of these small vessels.

3. Why do these brain spots show up more as I get older?

These brain changes are indeed common in the aging population. While there’s a strong genetic component that predisposes some individuals, the accumulation of subtle damage to the brain’s small blood vessels over many years, influenced by both genetics and other factors, contributes to their increased presence with age.

4. Will these brain changes affect my memory or thinking at work?

Yes, these brain changes are associated with general cognitive disorders and an increased risk of vascular cognitive impairment and dementia. The extent of these changes can correlate with how they impact your cognitive functions, including your memory and ability to think clearly.

5. Is there anything I can do to prevent these brain changes?

Understanding your genetic predisposition is a key step in prevention. While you can’t change your genes, managing known risk factors like hypertension is important, as it influences the genetic architecture of these changes. Research aims to use this genetic understanding for early detection and prevention strategies.

6. Are all these brain spots the same, or do they mean different things?

No, these brain spots can appear in different locations, specifically around the brain’s ventricles (periventricular) or in deeper white matter regions. Research suggests that common genetic variations may indicate distinct underlying causes for these different types of brain spots.

7. Could a genetic test tell me my personal risk for these brain changes?

Yes, genome-wide association studies have identified specific genetic variants associated with these brain changes. For example, variations in genes like PLEKHG1 and MRPL38 have been linked to them. A genetic test could potentially reveal some of your inherited predispositions, helping to assess your risk.

8. My sibling has these brain spots, but I don’t. Why the difference?

Even though these brain changes are highly heritable, meaning genetics play a big role, individual development is complex. While you share many genes with your sibling, unique genetic variations and environmental factors can lead to differences in how these changes manifest in each person.

9. Does my ethnic background change my risk for these brain spots?

Yes, research indicates that the genetic architecture for these brain changes can vary across different populations. Multi-ethnic studies are important because your ethnic background might influence your specific genetic risk factors and, therefore, your individual susceptibility.

10. Can exercise really overcome my family’s history of these brain spots?

While genetics heavily influence these brain changes, exercise is crucial for maintaining overall cardiovascular health, which directly impacts the small blood vessels in your brain. While you can’t completely “override” your genetic predisposition, a healthy lifestyle, including regular exercise, can help mitigate some risks and promote better brain health.

---

This FAQ was automatically generated based on current genetic research and may be updated as new information becomes available.

Disclaimer: This information is for educational purposes only and should not be used as a substitute for professional medical advice. Always consult with a healthcare provider for personalized medical guidance.

References

[1] Verhaaren BF, Debette S, Bis JC, et al. Multi-ethnic genome-wide association study of cerebral white matter hyperintensities on MRI. Circ Cardiovasc Genet 2015;8:398–409.

[2] Debette S, Markus HS. “The clinical importance of white matter hyperintensities on brain magnetic resonance imaging: systematic review and meta-analysis.” BMJ, vol. 341, 2010, p. c3666.

[3] Jian X, et al. “Exome Chip Analysis Identifies Low-Frequency and Rare Variants in MRPL38 for White Matter Hyperintensities on Brain Magnetic Resonance Imaging.” Stroke, vol. 49, no. 8, 2018, pp. 1812–1819. PMID: 30002152.

[4] Guo Y, et al. “Genome-wide association study of white matter hyperintensity volume in elderly persons without dementia.”Neuroimage Clin, vol. 26, 2020, p. 102209. PMID: 32062564.

[5] Traylor M, et al. “Genome-wide meta-analysis of cerebral white matter hyperintensities in patients with stroke.”Neurology, vol. 86, 2016, pp. 146–153. PMID: 26674333.

[6] Armstrong NJ, et al. “Common Genetic Variation Indicates Separate Causes for Periventricular and Deep White Matter Hyperintensities.” Stroke, vol. 49, 2018, pp. 1812–1819.

[7] Wardlaw JM, et al. “Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration.”Lancet Neurol, vol. 12, no. 8, 2013, pp. 822–838.

[8] Sargurupremraj M, Debette S, Schilling S, et al. Cerebral small vessel disease genomics and its implications across the lifespan. Nat Commun 2020;11:6213.

[9] Atwood LD, et al. “Genetic variation in white matter hyperintensity volume in the Framingham Study.”Stroke, vol. 35, 2004, pp. 1609–1613.

[10] Adib-Samii P, Devan W, Traylor M, et al. Genetic architecture of white matter hyperintensities differs in hypertensive and nonhypertensive ischemic stroke. Stroke 2015;46:348–353.

[11] Kuller LH, et al. “White matter hyperintensity on cranial magnetic resonance imaging: a predictor of stroke.”Stroke, vol. 35, 2004, pp. 1821–1825.

[12] Arsava EM, et al. “Severity of leukoaraiosis correlates with clinical outcome after ischemic stroke.”Neurology, vol. 72, 2009, pp. 1403–1410.

[13] Rost NS, et al. “White matter hyperintensity volume is increased in small vessel stroke subtypes.”Neurology, vol. 75, 2010, pp. 1670–1677.

[14] Chen YW, et al. “Progression of white matter lesions and hemorrhages in cerebral amyloid angiopathy.” Neurology, vol. 67, 2006, pp. 83–87.

[15] Rutten-Jacobs, L. C. A., et al. “Genetic Study of White Matter Integrity in UK Biobank (N=8448) and the Overlap With Stroke, Depression, and Dementia.”Stroke, vol. 49, 2018, pp. 1340–1347.

[16] Traylor M, et al. “Genetic variation in PLEKHG1 is associated with white matter hyperintensities (n = 11,226).” Neurology, vol. 92, no. 16, 2019, pp. e749–e757.

[17] Smith, S. M., et al. “An expanded set of genome-wide association studies of brain imaging phenotypes in UK Biobank.” Nat Neurosci, vol. 24, no. 5, 2021, pp. 737–745.

[18] Persyn E, et al. “Genome-wide association study of MRI markers of cerebral small vessel disease in 42,310 participants.”Nat Commun, vol. 11, 2020, p. 2225.

[19] Turner ST, et al. “Heritability of leukoaraiosis in hypertensive sibships.” Hypertension, vol. 43, 2004, pp. 483–487.

[20] Schmidt R, Schmidt H, Haybaeck J, et al. Heterogeneity in age-related white matter changes. Acta Neuropathol 2011;122:171–185.

[21] Zhukovsky P, Rutten-Jacobs L, Sargurupremraj M, et al. Genetic influences on brain and cognitive health and their interactions with cardiovascular conditions and depression. Nat Commun 2024;15:5135.

[22] Griffanti, L., et al. “BIANCA (Brain Intensity Abnormality Classification Algorithm): a new tool for automated segmentation of white matter hyperintensities.” Neuroimage, vol. 141, 2016, pp. 191–205.

[23] Fornage M, Debette S, Bis JC, et al. Genome-wide association studies of cerebral white matter lesion burden: the CHARGE consortium. Ann Neurol 2011;69:928–939.

[24] Armstrong NJ, et al. “Common Genetic Variation Indicates Separate Causes for Periventricular and Deep White Matter Hyperintensities.” Stroke, vol. 51, no. 7, 2020, pp. 2003-2011. PMID: 32517579.

[25] Opherk C, Peters N, Holtmannspotter M, et al. Heritability of MRI lesion volume in CADASIL: evidence for genetic modifiers. Stroke 2006;37:2684–2689.

[26] Lopez LM, Hill WD, Harris SE, et al. Genes from a translational analysis support a multifactorial nature of white matter hyperintensities. Stroke 2015;46:341–347.

[27] Fennema-Notestine C, et al. “White matter disease in midlife is heritable, related to hypertension, and shares some genetic influence with systolic blood pressure.”Neuroimage Clin, vol. 12, 2016, pp. 737–745.

[28] Wardlaw, J.M., Valdés Hernández, M.C., Muñoz-Maniega, S. “What are white matter hyperintensities made of?” Stroke, vol. 47, 2016, pp. 1679–1684.

[29] Malik, R. et al. “Whole-exome sequencing reveals a role of HTRA1 and EGFL8 in brain white matter hyperintensities.” Brain, vol. 144, no. 10, 2021, pp. 3060–3072.

[30] de Groot, M., Verhaaren, B.F., de Boer, R., et al. “Changes in normal-appearing white matter precede white matter hyperintensities.” Stroke, vol. 43, 2012, pp. 2680–2685.

[31] Fernando, M.S. et al. “White matter lesions in an unselected cohort of the elderly: Molecular pathology suggests origin from chronic hypoperfusion injury.” Stroke, vol. 37, no. 5, 2006, pp. 1391–1398.

[32] Nasrallah, I.M. et al. “Association of intensive vs standard blood pressure control with cerebral white matter lesions.” JAMA, vol. 322, no. 6, 2019, pp. 524–534.

[33] Albrecht, M. et al. “Remote ischemic preconditioning regulates hif-1alpha levels, apoptosis and inflammation in heart tissue of cardiosurgical patients: A pilot experimental study.” Basic Res Cardiol, vol. 108, no. 314, 2013.

[34] Provenzano, F.A. et al. “White matter hyperintensities and cerebral amyloidosis: necessary and sufficient for clinical expression of Alzheimer disease?”JAMA Neurol., vol. 70, no. 4, 2013, pp. 455–461.

[35] Garde, E., et al. “Relation between age-related decline in intelligence and cerebral white-matter hyperintensities in healthy octogenarians: A longitudinal study.”Lancet, vol. 356, no. 9230, 2000, pp. 628–634.

[36] Grimaud, J., et al. “Quantification of MRI lesion load in multiple sclerosis: a comparison of three computer-assisted techniques.”Magn Reson Imaging, vol. 14, 1996, pp. 495–505.

[37] Longstreth, W. T. Jr., et al. “Clinical correlates of white matter findings on cranial magnetic resonance imaging of 3301 elderly people. The Cardiovascular Health Study.”Stroke, vol. 27, 1996, pp. 1274–1282.